Prognostic Significance of PD-L1 Expression by Tumor-Associated Immune Cells in Serous Ovarian Carcinoma



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Current research is focused on the prognostic significance of tumor-infiltrating lymphocytes and activation of antitumor immune responses in ovarian carcinoma treatment.

AIM: The work aimed to analyze the relationships among overall survival, progression-free survival, clinical factors, and the expression of PD-L1, CD3, CD4, CD8, CD14, and CD16 receptors in tumors from patients with serous ovarian carcinoma.

MATERIAL AND METHODS: A prospective study was conducted to assess the expression of tumor-associated immune cells (i.e., CD3, CD4, CD8, CD14, and CD16) and PD-L1 receptor using immunohistochemistry in the tumor microenvironment of 120 patients with serous ovarian carcinoma treated at the Primorsky Regional Oncology Dispensary between 2019 and 2021. Based on the histological type of epithelial ovarian carcinoma, high-grade serous carcinoma was identified in 81.7% patients and low-grade serous carcinoma in 18.3%. Primary cytoreductive surgery was conducted in 70.0% cases. Complete or optimal cytoreduction was achieved in 57.5% primary and interval surgeries. The patients received combination therapy, with platinum- and taxane-based regimens used as first-line chemotherapy. BRCA1/2 gene mutations were identified in 28.3% patients with ovarian carcinoma. Additionally, PD-L1 expression was positive in 39.2% patients, notably in 14 patients with high-grade serous carcinoma. None of the patients with PD-L1 expression >1% had BRCA1/2 mutations. Primary treatment, involving surgical intervention combined with cycles of antitumor chemotherapy, was administered at the Primorsky Regional Oncology Dispensary between 2019 and 2021. Statistical analyses included comparison of overall and progression-free survival using the Kaplan–Meier method. Survival comparisons were performed using the log-rank test. Cox regression analysis was used to evaluate hazard ratios of various clinical and pathologic factors.

RESULTS: Overall survival in patients with serous ovarian carcinoma was significantly influenced by: 1) disease stage, 2) tumor grade, and 3) timing, and extent of cytoreduction. Positive PD-L1 expression was observed in 14.3% patients with high-grade serous carcinoma and was associated with better progression-free survival (p = 0.007).

CONCLUSION: Death and disease progression risks in serous ovarian carcinoma decrease in the absence of PD-L1 expression. Higher survival rates were associated with the expression of CD3, CD4, and CD8 in the tumor.

About the authors

Varvara N. Zhurman

Primorsky Regional Oncological Dispensary; Pacific State Medical University

Author for correspondence.
Email: varvara2007@yandex.ru
ORCID iD: 0000-0002-6927-3336
SPIN-code: 1781-0007

MD, Cand. Sci. (Medicine), Assistant ­Professor, Depart. of Obstetrics and Gynecology

Russian Federation, Vladivostok; Vladivostok

Valentina M. Nechushkina

Eurasian Oncological Program «EAFO»; Privolzhsky Research Medical University

Email: drnechushkina@mail.ru
ORCID iD: 0000-0002-1855-9692
SPIN-code: 8523-6798

MD, Dr. Sci. (Medicine), Professor, Depart. of Obstetrics and Gynecology

Russian Federation, Moscow; Nizhny Novgorod

Natalia G. Plekhova

Pacific State Medical University

Email: pl_nat@hotmail.com
ORCID iD: 0000-0002-8701-7213
SPIN-code: 2685-9578

MD, Dr. Sci. (Biology), Head, Central Res. Lab.

Russian Federation, Vladivostok

References

  1. Clinical recommendations. Ovarian cancer, fallopian tube cancer, primary peritoneal cancer 2020-2021-2022 (01/31/2023). Ministry of Health of the Russian Federation. 47 p. [cite 2024 Oct 9]. Available from: http://disuria.ru/_ld/13/1326_kr20C48C56C57MZ.pdf
  2. Tyulyandina AS, Kolomiets LA, Morkhov KYu, et al. Practical recommendations for the drug treatment of ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Practical recommendations of RUSSCO, part 1. Malignant tumors. 2023;13(3s2):201–215. doi: 10.18027/2224-5057-2022-12-3s2-198-211 EDN: ULYRJB
  3. Khabarov SV, Nikoghosyan SO, Volkov VG, Chibisova GM. Optimization of early diagnosis of ovarian cancer using the modern original ScOv software package. Tumors of the female reproductive system. 2019;2:71–76. doi: 10.17650/1994-4098-2019-15-2-71-76 EDN: CIGKLS
  4. Chang LC, Huang CF, Lai MS, et al. Prognostic factors in epithelial ovarian cancer: a population-based study. PLoS One. 2018;13(3):019499. doi: 10.1371/journal.pone.0194993
  5. Kumar A, Cliby WA. Advanced ovarian cancer: weighing the risks and benefits of surgery. Clin Obstet Gynecol. 2020;63(1):74–79. doi: 10.1097/GRF.0000000000000497 EDN: BJZAIU
  6. Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. Clinical Trial N Engl J Med. 2019;381(20):1929–1939. doi: 10.1056/NEJMoa1902626
  7. Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30(11):1657–1664. doi: 10.1136/ijgc-2020-001640 EDN: GHSMBJ
  8. Harter P, Sehouli J, Vergote I, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. Randomized controlled trial. N Engl J Med. 2021;385(23):2123-2131. doi: 10.1056/NEJMoa2103294 EDN: CSIIOJ
  9. Zhurman VN. Influence of molecular genetic characteristics on the prognosis of newly diagnosed high-grade III–IV stage serous ovarian cancer, depending on treatment options. Volga Cancer Bulletin. 2022;13(4(52)):17–24. doi: 10.32000/2078-1466-2022-4-17-24 EDN: BWMWRB
  10. Gonzalez H, Hagerling С, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Review Genes Dev. 2018;32(19–20):1267–1284. doi: 10.1101/gad.314617.118 EDN: WWGACZ
  11. Wang Q, Loua W, Dia W, Wu X. Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int Immunopharmacol. 2017;52:7–11. doi: 10.1016/j.intimp.2017.08.017 EDN: YJFTPY
  12. Tomsová M, Melichar В, Sedláková I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovariancarcinoma. Gynecol Oncol. 2008;108(2):415–420. doi: 10.1016/j.ygyno.2007.10.016
  13. Chen K, Zhu Z, Zhang N, et al. Tumor-infiltrating CD4+ lymphocytes predict a favorable survival in patients with operable esophageal squamous cell carcinoma. Med Sci Monit. 2017;23:4619–4632. doi: 10.12659/msm.904154
  14. Waki K, Kawano K, Tsuda N. CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients. Cancer Sci. 2020;111(4):1124–1131. doi: 10.1111/cas.14349 EDN: RJPNOH
  15. Wouters MCA, Komdeur F, Workle HH, et al. Treatment regimen, surgical outcomes, and t-cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high-grade serous ovarian cancer. Clinical Cancer Research. 2015;22(3):714–724. doi: 10.1158/1078-0432.CCR-15-1617 EDN: YDVOMM
  16. Nersesian S, Arseneau RJ, Mejia JP, et al. Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages. Front Immunol. 2024;14:1307873. doi: 10.3389/fimmu.2023.1307873 EDN: OYSWMV
  17. Winkler I, Wilczynska B, Bojarska-Junak A, et al. Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance. J Ovarian Res. 2015;8:39. doi: 10.1186/s13048-015-0164-0 EDN: SEHESM
  18. Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8(57):97671–97682. doi: 10.18632/oncotarget.18311
  19. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–895. doi: 10.1084/jem.20051776
  20. Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458(7235):206–210. doi: 10.1038/nature07662
  21. Bansal A, Srinivasan R, Rohilla M, et al. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival. APMIS. 2021;129(5):254–264. doi: 10.1111/apm.13116 EDN: IDPJFQ
  22. Webb JR, Milne K, Kroeger DR. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serious ovarian cancer. Gynecol Oncol. 2016;141(2):293–302. doi: 10.1016/j.gino.2016.03.008
  23. Chen H, Molberg K, Strickland AL, et al. PD-L1 Expression and CD8+ tumor-infiltrating lymphocytes in different types of tubo-ovarian carcinoma and their prognostic value in high-grade serous carcinoma. Am J Surg Pathol. 2020;44(8):1050–1060. doi: 10.1097/PAS.0000000000001503 EDN: XAZRRF
  24. Kim KS, Sekar RR, Patil D, et al. Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. Oncoimmunology. 2018;7(4):e1413519. doi: 10.1080/2162402X.2017.1413519
  25. Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206(6):1327–1337. doi: 10.1084/jem.20082173
  26. Andrusova NN, Kolganova MA, Alyoshina AV, Shohin IE. PD-L1 as a potential target in anticancer therapy. Development and registration of medicines. 2021;10(1):31–36. doi: 10.33380/2305-2066-2021-10-1-31-36 EDN: CKMIWQ
  27. De Decker K, Wenzel HHB, Bart J, et al. Sewage, treatment and survival of low-grade squamous ovarian carcinoma in the Netherlands: a nationwide study. Acta Obstet Gynecol Scand. 2023;102(3):246–256. doi: 10.1111/aogs.14518 EDN: NGSXDX
  28. Seidman JD, Yemelyanova A, Cosin JA, et al. Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. Int J Gynecol Cancer. 2012;22(3):367–371. doi: 10.1097/IGC.0b013e31823c6f80
  29. Trimbos JB, Timmers P, Pecorelli S, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst. 2010;102(13):982–987. doi: 10.1093/jnci/djq149
  30. Haunschild C, Tewari КS. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Review Future Oncol. 2020;16(7):225–246. doi: 10.2217/fon-2019-0042 EDN: CBDAVF
  31. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. Comparative Study J Clin Oncol. 2008;26(1):20–25. doi: 10.1200/JCO.2007.11.6905

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

© 2025 Eco-Vector